Globus Medical (GMED) Shares Slide -11.8%

Globus Medical (GMED) : During the past 4 weeks, traders have been relatively bearish on Globus Medical (GMED), hence the stock is down -9.33% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -11.74% relative to the S&P 500. The 4-week change in the price of the stock is -6.29% and the stock has fallen -11.8% in the past 1 week.

The stock has recorded a 20-day Moving Average of 7.2% and the 50-Day Moving Average is 5.69%. Globus Medical, Inc. has dropped 8.35% during the last 3-month period . Year-to-Date the stock performance stands at -17.51%.


Globus Medical (NYSE:GMED): stock turned positive on Friday. Though the stock opened at $22.45, the bulls momentum made the stock top out at $23.06 level for the day. The stock recorded a low of $22.45 and closed the trading day at $22.95, in the green by 2.09%. The total traded volume for the day was 1,050,469. The stock had closed at $22.48 in the previous days trading.

Globus Medical, Inc. is a medical device company. The Company is focused on developing products for patients with musculoskeletal disorders and spine disorders. Its products consist of two categories: Innovative Fusion and Disruptive Technologies. Innovative Fusion products comprise fusion products to treat various spinal disorders for the entire spine and can be used in various surgical approaches. Disruptive Technologies represents a shift in the treatment of spinal disorders by allowing for surgical procedures and the treatment of spinal disorders. The Companys portfolio of Disruptive Technology products includes products that allow for minimally invasive surgical (MIS) techniques, as well as treatment alternatives, including motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and biomaterials technologies, as well as interventional pain management solutions.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.